• Committing to science and discovery.

  • Guided by compassion and respect.

  • Patients are our priority.

MiRx is poised to become a preeminent oncology company focused on developing innovative drugs to improve the lives of the Acute Myeloid Leukemia (AML) patients and their families. Our pipeline includes therapeutic candidates in pre-clinical through early-stage clinical development. AML therapeutics market was USD 239.3 million in 2011 and this market is forecasted to reach USD 731.1 million in 2018. The reasons behind the huge growth rate are increase in ageing population.

MiRx is a privately held specialty pharmaceutical company based in Lexington, KY engaged in multiple drug discovery program in cancer. We are independently and aggressively working towards AML prevention through non conventional way. Company is heavily funded through NCI SBIR program and State of Kentucky business development program (KSTC).

We welcome partnerships and leveraging our company’s strong product pipeline, we have the opportunity to make significant medical advancements towards AML that can help patients live better lives.

At Mirx everyone can learn from some of the brightest minds in the industry while applying their own knowledge, skills, and expertise in a collaborative and supportive environment. Successful professionals with an entrepreneurial spirit, our leadership team is composed of senior pharmaceutical and biotechnology professionals who have extensive experience in R&D operations and commercialization.

At Mirx we are committed to creating a culture that encourages responsible corporate action at every level of our organization. We strive for the highest standards of business conduct and work ethics.